* Oculis's privosegtor (OCS-05) is entering Phase 3 trials for acute optic neuritis (AON) and non-arteritic anterior ischemic optic neuropathy (NAION), addressing significant unmet medical needs in neuro-ophthalmology
It was approved by the US Food and Drug Administration (FDA) as a 2-line drug for T2DM patients in 2005, and was marketed in China in 2009
It supports younger individuals seekingproactive longevity support, as well as adultsexperiencing age-related decline or heightened repairneeds due to stress, training, or recovery
Rybelsus (oral semaglutide) Summary of Product Characteristics
Plus, both medications may help with health issues related to being overweight or having obesity, such as joint pain, sleep apnea, and fatigue, says Connor